Skip to main content

Advertisement

SpringerLink
Log in

A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients

  • Review
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Background

Ovarian cancer is the deadliest of gynecologic malignancies with the 5-year overall survival rate remaining at approximately 30%, a rate that has not improved over the last three decades. Standard of care for epithelial ovarian cancer patients consists of a platinum compound with a taxane given intravenously following debulking surgery; however, 80% of cases relapse within 2 years of diagnosis. This review sought to identify key underlying biomarkers related to platinum resistance in ovarian cancer to establish possible prognostic biomarkers of chemoresponse.

Methods

A systematic literature review was conducted across three databases PubMed, EMBASE and SCOPUS to summarise the evidence for prognostic biomarkers in platinum-resistant ovarian cancer patients.

Results

Forty-eight human studies were used in the review encompassing 6719 participants in retrospective and prospective study designs. A total of 68 biomarkers were reported that were significantly correlated with chemoresponse and/or survival reporting a p value less than or equal to 0.05.

Conclusion

This review accentuates the pleiotropic phenotypic complexities related to the response to platinum therapy in ovarian cancer. A one-size-fits-all approach may be ineffective in a large portion of patients, emphasising the need for a whole system-based approach and personalised treatment strategies. Identifying key biomarkers to aid clinical decision-making is the first essential step in developing and appropriating therapies for at-risk patients, reducing toxicity and improving quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. DNA adducts are a piece of DNA bound to a chemical. In this instance, platinum drug becomes incorporated into the DNA as an adduct, thus being referred to as a platinum adduct [69].

References

  1. Cancer Australia. Gynaecological cancer statistics | Gynaecological cancers [Internet]. 2019 [cited 2019 Jun 23]. Available from: https://gynaecological-cancer.canceraustralia.gov.au/statistics

  2. The World Ovarian Cancer Coalition. THE WORLD OVARIAN CANCER COALITION ATLAS GLOBAL TRENDS IN INCIDENCE, MORTALITY AND SURVIVAL [Internet]. 2018 [cited 2019 Jun 23]. Available from: https://worldovariancancercoalition.org/wp-content/uploads/2018/10/THE-WORLD-OVARIAN-CANCER-COALITION-ATLAS-2018.pdf

  3. Koukoura O, Spandidos DA, Daponte A, Sifakis S (2014) DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review). Mol Med Rep 10(1):3–9 [cited 2018 Apr 12] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24821107

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer epidemiology and risk factors. Lancet 374:1371–1382 [cited 2018 Apr 25] Available from: https://ac-els-cdn-com.ezproxy.endeavour.edu.au/S0140673609613386/1-s2.0-S0140673609613386-main.pdf?_tid=f2835517-bfce-4c7c-9485-a51847e13492&acdnat=1524641109_7eff38fc2b115db1fdcf927850752e74

    CAS  PubMed  Google Scholar 

  5. Assis J, Pereira C, Nogueira A, Pereira D, Carreira R, Medeiros R (2017) Systematic or Meta-analysis Studies Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis. Cancer Treat Rev 61:35–52 [cited 2018 Mar 5] Available from: https://ac-els-cdn-com.ezproxy.endeavour.edu.au/S0305737217301573/1-s2.0-S0305737217301573-main.pdf?_tid=f9d726e8-f268-461b-843e-b58f1e4ac5f1&acdnat=1520236476_95a61e584d1650ad85e98bd84968cfd5

    CAS  PubMed  Google Scholar 

  6. Balch C, Fang F, Matei DE, H-M Huang T, Nephew KP (2009) Minireview: Epigenetic changes in ovarian cancer. Endocrinology 150:4003–4011 [cited 2018 Apr 23] Available from: https://watermark.silverchair.com/endo4003.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAacwggGjBgkqhkiG9w0BBwagggGUMIIBkAIBADCCAYkGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM65q06z4u2fPcJQWXAgEQgIIBWr1IQTegcQu_ozrV4cmUXoxJeMH3p38G76EFzYumWyijB7

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R (2004) The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10:4420–4426 [cited 2017 Nov 6] Available from: http://clincancerres.aacrjournals.org/content/clincanres/10/13/4420.full.pdf

    CAS  PubMed  Google Scholar 

  8. Thompson M, Tiwari A, Fu R, Moe E, Buckley DI (2012) A Framework To Facilitate the Use of Systematic Reviews and Meta-Analyses in the Design of Primary Research Studies [Internet]. A Framework To Facilitate the Use of Systematic Reviews and Meta-Analyses in the Design of Primary Research Studies. Agency for Healthcare Research and Quality (US); [cited 2018 Apr 12]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22299187

  9. STROBE Statement. STROBE Statement: Available checklists [Internet]. 2007 [cited 2018 Apr 12]. p. 2015. Available from: http://www.strobe-statement.org/index.php?id=available-checklists

  10. Abdel-Fatah TMA, Arora A, Moseley P, Coveney C, Perry C, Johnson K, Kent C, Ball G, Chan S, Madhusudan S (2014) ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin 2:10–17 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906734176&doi=10.1016%2Fj.bbacli.2014.08.001&partnerID=40&md5=97a0166b2568e8b7ec72f83241ca5618

    PubMed  PubMed Central  Google Scholar 

  11. Alanee S, Delfino K, Wilber A, Robinson K, Brard L, Semaan A (2017) Single nucleotide variant in Nucleoporin 107 may be predictive of sensitivity to chemotherapy in patients with ovarian cancer. Pharmacogenet Genomics 27(7):264–269 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020130048&doi=10.1097%2FFPC.0000000000000288&partnerID=40&md5=c5a96aa32a5271aefc6bac72d727bd83

  12. Alsop K, Fereday S, Meldrum C, de Fazio A, Emmanuel C, George J et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654–2663 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413277/pdf/zlj2654.pdf

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Ayub TH, Keyver-Paik MD, Debald M, Rostamzadeh B, Thiesler T, Schröder L et al (2015) Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer. Oncotarget 6(18):16437–16448 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937819035&doi=10.18632%2Foncotarget.4103&partnerID=40&md5=610786605fb4cbf6b7553441d62c7d71

    PubMed  PubMed Central  Google Scholar 

  14. Chen M, Yao S, Cao Q, Xia M, Liu J, He M (2017) The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients. Oncotarget 8(64):107877–107885 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037345411&doi=10.18632%2Foncotarget.14112&partnerID=40&md5=871a1f59f0ed0c79db0a81470dcb7173

    PubMed  Google Scholar 

  15. Despierre E, Moisse M, Yesilyurt B, Sehouli J, Braicu I, Mahner S, Castillo-Tong DC, Zeillinger R, Lambrechts S, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I (2014) Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. Gynecol Oncol 135(3):415–422 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920761535&doi=10.1016%2Fj.ygyno.2014.09.014&partnerID=40&md5=23dc959b05e00998cde5dc4a9fd7667a

    CAS  PubMed  Google Scholar 

  16. Du P, Wang Y, Chen L, Gan Y, Wu Q (2016) High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer. Oncol Lett 12(2):857–862 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84977083806&doi=10.3892%2Fol.2016.4732&partnerID=40&md5=7a52a334934eb2f087ab9413a6e78a80

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H (2009) Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 114(2):253–259 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-67549139894&doi=10.1016%2Fj.ygyno.2009.04.024&partnerID=40&md5=86c2583feed15d430e55459aacaaa34b

    CAS  PubMed  Google Scholar 

  18. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zucconi A, Santaguida S, Zannoni G, Scambia G, Ferlini C (2008) Prognostic role of the recepteur d’origine nantais (RON) expression in ovarian cancer patients. Gynecol Oncol 111(2):237–243 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-55649116204&doi=10.1016%2Fj.ygyno.2008.07.013&partnerID=40&md5=f4bb850b101cd449ff6014d3d4baf549

    CAS  PubMed  Google Scholar 

  19. Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A, Scambia G (2008) Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients. Br J Cancer 98(12):1910–1915 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-44949133943&doi=10.1038%2Fsj.bjc.6604410&partnerID=40&md5=0ae8ff9bfac2916c2251f802fc54aa7b

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Ge L, Li N, Liu M, Xu NZ, Wang MR, Wu LY (2017) Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer. Medicine (Baltimore) ;96(30). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026368347&doi=10.1097%2FMD.0000000000007621&partnerID=40&md5=4094e3cfa46c2ba7eee041961c43867d

  21. Helleman J, Jansen MPHM, Span PN, Van Staveren IL, Massuger LFAG, Meijer-Van Gelder ME et al (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118(8):1963–1971 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645220428&doi=10.1002%2Fijc.21599&partnerID=40&md5=e1831c4f2ad43b6c127438d4bdc88ff4

    CAS  PubMed  Google Scholar 

  22. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R et al (2010) The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res 18(7):343–347 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-77950558564&doi=10.3727%2F096504010X12626118079903&partnerID=40&md5=62f1e834ef12cbc1b1e80508c4e1ac3f

    PubMed  Google Scholar 

  23. Iramaneerat K, Rattanatunyong P, Khemapech N, Triratanachat S, Mutirangura A (2011) HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance. Int J Gynecol Cancer 21(1):51–57 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79951497457&doi=10.1097%2FIGC.0b013e3182021c1a&partnerID=40&md5=1a6327f9f220572b6595ce0b036382d3

  24. Jin Y, Feng LP, Jiang X, Wang YX, Yin J, Yang ZP, Li Y, Pan LY (2015) Annexin A3 is a potential predictor of platinum resistance in epithelial ovarian cancer patients in a prospective cohort. J Cancer 6(7):678–685 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938378831&doi=10.7150%2Fjca.11689&partnerID=40&md5=7204d81f709b92f5e2e67d8a21db416f

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Ju LL, Zhao CY, Ye KF, Yang H, Zhang J (2016) Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. Eur Rev Med Pharmacol Sci 20(10):1993–2003 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84981721941&partnerID=40&md5=3234a20630a18099a9175ad07f961060

    PubMed  Google Scholar 

  26. Kang S, Ju W, Jae WK, Park NH, Song YS, Seung CK et al (2006) Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38(3):320–324 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745830472&doi=10.1038%2Femm.2006.38&partnerID=40&md5=99659866a292de9c19bd3e3a0a8097a9

    CAS  PubMed  Google Scholar 

  27. Kucukgoz Gulec U, Gumurdulu D, Guzel AB, Paydas S, Seydaoglu G, Acikalin A, Khatib G, Zeren H, Vardar MA, Altintas A (2014) Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma. Arch Gynecol Obstet 289(2):393–398 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84895129385&doi=10.1007%2Fs00404-013-3000-z&partnerID=40&md5=17290f7ae1a4374e04790fe670ef9470

    CAS  PubMed  Google Scholar 

  28. Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F, Kimmig R, Kasimir-Bauer S (2014) ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem 60(10):1282–1289 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84921821089&doi=10.1373%2Fclinchem.2014.224808&partnerID=40&md5=566ecd989cfd6d8b3ba72c5b1b70f433

    CAS  PubMed  Google Scholar 

  29. Makhija S, Sit A, Edwards R, Aufman K, Weiss H, Kanbour-Shakir A, Gooding W, D’Angelo G, Ferrell R, Raja S, Godfrey TE (2003) Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Gynecol Oncol 90(1):3–9 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038500746&doi=10.1016%2FS0090-8258%2803%2900177-X&partnerID=40&md5=2a071145412f30a9bcf1d175283ef737

    CAS  PubMed  Google Scholar 

  30. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, Milani R, Torri V, Romualdi C, Zambelli A, Romano M, Signorelli M, Giandomenico S, D’Incalci M (2013) Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer 49(2):520–530 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872114095&doi=10.1016%2Fj.ejca.2012.06.026&partnerID=40&md5=112506fc829efd9e3b41251f91847d93

    CAS  PubMed  Google Scholar 

  31. Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, et al. (2016) Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. J Ovarian Res. 9(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969560249&doi=10.1186%2Fs13048-016-0238-7&partnerID=40&md5=0bc857edc1db7116e0fcbf8c3fbda567

  32. Muallem MZ, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R (2014) ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer. Anticancer Res 34(1):393–399 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897026223&partnerID=40&md5=cc945c40072ed2f0f441399be95e6013

    CAS  PubMed  Google Scholar 

  33. Österberg L, Levan K, Partheen K, Staaf J, Sundfeldt K, Horvath G (2009) High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cytogenet Genome Res 125(1):8–18 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-67849097084&doi=10.1159%2F000218744&partnerID=40&md5=0478f79ab6e44e84d8cf8dea0862c4fa

  34. Palmieri C, Gojis O, Rudraraju B, Stamp-Vincent C, Wilson D, Langdon S, Gourley C, Faratian D (2013) Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br J Cancer 108(10):2039–2044 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878570781&doi=10.1038%2Fbjc.2013.199&partnerID=40&md5=e37cf98313ad023b267a004f6d027d04

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH et al (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20(3):764–775 Available from: http://clincancerres.aacrjournals.org/content/clincanres/20/3/764.full.pdf

    CAS  PubMed  Google Scholar 

  36. Pylväs-Eerola M, Karihtala P, Puistola U (2015) Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer. BMC Cancer;15(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84934768455&doi=10.1186%2Fs12885-015-1504-6&partnerID=40&md5=852609175e49d2d8716fbe64ef41ff42

  37. Pylväs-Eerola M, Liakka A, Puistola U, Koivunen J, Karihtala P (2016) Cancer stem cell properties as factors predictive of chemoresistance in neoadjuvantly-treated patients with ovarian cancer. Anticancer Res 36(7):3425–3432 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979895446&partnerID=40&md5=61b93e4fd4baf85066c793b54f242656

  38. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Muller-Holzner E, Marth C, Zeimet AG (2007) Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. Clin Cancer Res 13(1):144–151 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846312460&doi=10.1158%2F1078-0432.CCR-06-0780&partnerID=40&md5=dbdc67080ef52ee0abdd9a7791504481

    CAS  PubMed  Google Scholar 

  39. Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC (2012) Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a gynecologic oncology group study. Gynecol Oncol 125(2):421–426 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859570977&doi=10.1016%2Fj.ygyno.2012.01.008&partnerID=40&md5=962b3c87be0e53590fa88a71c51e9834

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, Follen M, Wu X (2007) Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 107(1 SUPPL):S223–S229 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-34748848707&doi=10.1016%2Fj.ygyno.2007.07.024&partnerID=40&md5=f1d27ea5fc6b73770437e152d91886de

    PubMed  Google Scholar 

  41. Sapoznik S, Aviel-Ronen S, Bahar-Shany K, Zadok O, Levanon K (2017) CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance. Oncotarget 8(37):62240–62247 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028746999&doi=10.18632%2Foncotarget.19272&partnerID=40&md5=f430b87a4ff9314bc5abb37d2fe0ab30

    PubMed  PubMed Central  Google Scholar 

  42. Scalici JM, Arapovic S, Saks EJ, Atkins KA, Petroni G, Duska LR, Slack-Davis JK (2017) Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). Cancer 123(6):977–984 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84998723875&doi=10.1002%2Fcncr.30415&partnerID=40&md5=2d7d4d0627ec42ed8241b57ced66e246

    CAS  PubMed  Google Scholar 

  43. sadf

  44. Shehata M, Mukherjee A, Deen S, Al-Attar A, Durrant LG, Chan S (2009) Human leukocyte antigen class i expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. Br J Cancer 101(8):1321–1328 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349975961&doi=10.1038%2Fsj.bjc.6605315&partnerID=40&md5=353801f083c30e2160f23f6d366aaf5c

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Smith S, Su D, Rigault De La Longrais IA, Schwartz P, Puopolo M, Rutherford TJ et al (2007) ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25(33):5172–5179 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-36849044583&doi=10.1200%2FJCO.2007.11.8547&partnerID=40&md5=38c443dd89bab3b016e9d59ba1d21344

    CAS  PubMed  Google Scholar 

  46. Sohn I, Jung WY, Sung CO (2012) Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer. Gynecol Oncol 126(1):103–108 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862758076&doi=10.1016%2Fj.ygyno.2012.03.050&partnerID=40&md5=43f006112016b25d58aabf67759618d1

    CAS  PubMed  Google Scholar 

  47. Steffensen KD, Smoter M, Waldstrøm M, Grala B, Bodnar L, Stec R et al (2014) Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and tau expression. Int J Oncol 44(5):1736–1744 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899078719&doi=10.3892%2Fijo.2014.2311&partnerID=40&md5=a6b9b8f38a1e83872459bb0544478a27

    CAS  PubMed  Google Scholar 

  48. Steffensen KD, Waldstrøm M, Jakobsen A (2009) The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 19(5):820–825 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-69449090272&doi=10.1111%2FIGC.0b013e3181a12e09&partnerID=40&md5=b0aa32bdc6d0e4cb686217fca637c235

    PubMed  Google Scholar 

  49. Steffensen KD, Waldstrom M, Jeppesen U, Brandslund I, Jakobsen A (2008) Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 18(4):702–710 Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1525-1438.2007.01068.x/abstract

    CAS  PubMed  Google Scholar 

  50. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68(8):2581–2586 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-42349096328&doi=10.1158%2F0008-5472.CAN-08-0088&partnerID=40&md5=5a3452b1a2bfe0f2e614a552489eeb77

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Wang Y, Li M, Meng F, Lou G (2017) HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer. Hum Pathol 60:114–120 Available from:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007188973&doi=10.1016%2Fj.humpath.2016.10.015&partnerID=40&md5=306e69555f686f8efa91c99823f7e036

  52. Wang XY, Wang HJ, Li XQ (2013) Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. Tumor Biol 34(4):2275–2281 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881479800&doi=10.1007%2Fs13277-013-0769-0&partnerID=40&md5=875214c27e28eb6e9c4b36e8b8cbedda

  53. Wilczyński M, Żytko E, Szymańska B, Dzieniecka M, Nowak M, Danielska J, Stachowiak G, Wilczyński JR (2017) Expression of miR-146a in patients with ovarian cancer and its clinical significance. Oncol Lett 14(3):3207–3214 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026313182&doi=10.3892%2Fol.2017.6477&partnerID=40&md5=9ff8c63c9fdb6265f503c5d51a906be0

  54. Wu W, Wang Q, Yin F, Yang Z, Zhang W, Gabra H, Li L (2016) Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer. Int J Oncol 49(4):1651–1665 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84990032661&doi=10.3892%2Fijo.2016.3652&partnerID=40&md5=649cc16a9c0b070d93c30eec115e842b

    CAS  PubMed  Google Scholar 

  55. Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, et al. (2012) BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One. 7(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855698070&doi=10.1371%2Fjournal.pone.0030042&partnerID=40&md5=e55eb2e0b15340304b1bdd08412b279b

  56. Zhang M, Liu T, Xia B, Yang C, Hou S, Xie W, Lou G (2018) Platelet-derived growth factor D is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer. Int J Gynecol Cancer 28(2):323–331 Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L620566006

    CAS  PubMed  Google Scholar 

  57. Zhao YN, He DN, Wang YD, Li JJ, Ha MW (2016) Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer. Oncol Lett 11(4):2925–2933 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960403826&doi=10.3892%2Fol.2016.4311&partnerID=40&md5=bd59ca8a374b424f492d3c3f3b31204c

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Rodriguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17(3):330–339 [cited 2018 Apr 23] Available from: http://eds.b.ebscohost.com.ezproxy.endeavour.edu.au/eds/pdfviewer/pdfviewer?vid=2&sid=d171c587-c003-4a1e-aa30-487fbe557f79%40sessionmgr120

    CAS  PubMed  Google Scholar 

  59. Cepeda V, Fuertes M, Castilla J, Alonso C, Quevedo C, Perez J (2007) Biochemical mechanisms of cisplatin cytotoxicity. Anti Cancer Agents Med Chem 7(1):3–18 [cited 2018 Apr 24] Available from: http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5206&volume=7&issue=1&spage=3

    CAS  Google Scholar 

  60. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P et al (2009) Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genet 2:1–13

    Google Scholar 

  61. Emran AA, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR et al (2019) Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. 40, Trends in Immunology. Elsevier Ltd:328–344

  62. Maeda M, Murakami Y, Watari K, Kuwano M, Izumi H, Ono M (2015) CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines. Lung Cancer 87(3):265–271

    PubMed  Google Scholar 

  63. Christmann M, Pick M, Lage H, Schadendorf D, Kaina B (2001) Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene mgmt. Int J Cancer 92(1):123–129

    CAS  PubMed  Google Scholar 

  64. Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J (2014) Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer 14:747–753 [cited 2020 Feb 23] Available from: https://www.researchgate.net/publication/266152021

    CAS  PubMed  Google Scholar 

  65. Shen D-W, Pouliot LM, Hall MD, Gottesman MM (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64(3):706–721 [cited 2018 Apr 25] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400836/pdf/zpg706.pdf

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Dziadkowiec KN (2016) PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Menopause Rev 15(4):215–219 [cited 2018 Apr 24] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/pdf/MR-15-29355.pdf

    CAS  Google Scholar 

  67. Esteller M (2008) Molecular origins of cancer epigenetics in cancer. N Engl J Med 358:1148–1159 [cited 2018 Apr 24] Available from: http://sholmes.web.wesleyan.edu/wescourses/2007f/mbb506/01/N Engl J Med 2008 Esteller.pdf

    CAS  PubMed  Google Scholar 

  68. McCoy ML, Mueller CR, Roskelley CD (2003) The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod Biol Endocrinol 1(72):1–5 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC270004/pdf/1477-7827-1-72.pdf

    Google Scholar 

  69. Kelland LR (2000) Preclinical perspectives on platinum resistance. Drugs 59(Supplement 4):1–8 Available from: http://link.springer.com/10.2165/00003495-200059004-00001

    CAS  PubMed  Google Scholar 

  70. Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14(5):1291–1295 [cited 2018 Apr 23] Available from: https://pdfs.semanticscholar.org/312f/180244778d0b2e9978be11f69f2f47619967.pdf

    CAS  PubMed  Google Scholar 

  71. Chen H-Y, Shao C-J, Chen F-R, Kwan A-L, Chen Z-P (2010) Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer 126(8):1944–1954 [cited 2018 Apr 12] Available from: http://doi.wiley.com/10.1002/ijc.24772

    CAS  PubMed  Google Scholar 

  72. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M et al (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25(19):2747–2754 [cited 2018 Apr 25] Available from: http://ascopubs.org/doi/10.1200/JCO.2006.09.7915

    CAS  PubMed  Google Scholar 

  73. Park SY, Kwon HJ, Choi Y, Lee HE, Kim S-W, Kim JH et al (2012) Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Mod Pathol 25160:185–196 [cited 2018 Apr 12] Available from: https://www.nature.com/articles/modpathol2011160.pdf

    Google Scholar 

  74. Watanabe Y, Ueda H, Etoh T, Koike E, Funjinami N, Mitsuhashi A et al (2007) A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian Cancer. Anticancer Res 27(3b):1449–1452 Available from: http://ar.iiarjournals.org/content/27/3B/1449.abstract

    CAS  PubMed  Google Scholar 

  75. Cheng D, Wu R, Guo Y, Kong A-NT (2016) Regulation of Keap1-Nrf2 signaling: the role of epigenetics. Curr Opin Toxicol 1:134–138 [cited 2018 Apr 23] Available from: http://www.ncbi.nlm.nih.gov/pubmed/29057383

    PubMed  PubMed Central  Google Scholar 

  76. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-Ngam D, et al. (2004) Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. [cited 2018 Apr 23]; Available from: https://www.nature.com/articles/1208137.pdf

  77. Yan B, Yin F, Wang Q, Zhang W, Li L (2016) Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer. Oncol Lett 12(1):157–166 [cited 2019 Feb 2] Available from: https://www.spandidos-publications.com/10.3892/ol.2016.4608

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Matei D, Ghamande S, Roman L, Secord AA, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF (2018) A phase i clinical trial of guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer: clinical, pharmacokinetic, and pharmacodynamic analyses. Clin Cancer Res 24(10):2285–2293 Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047795984&doi=10.1158%2F1078-0432.CCR-17-3055&partnerID=40&md5=dc898773e69062f40c598a145db7213d

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Crider KS, Yang TP, Berry RJ, Bailey LB (2012) Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’s role 1,2. Adv Nutr 3:21–38 [cited 2017 Nov 2] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262611/pdf/21.pdf

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Dixon SC, Ibiebele TI, Protani MM, Beesley J, Defazio A, Crandon AJ et al (2014) Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. Gynecol Oncol 132:566–572. [cited 2019 Jan 22] Available from. https://doi.org/10.1016/j.ygyno.2013.12.025

    Article  CAS  PubMed  Google Scholar 

  81. Habel N, Hamidouche Z, Girault I, Patiñ O-Garcıá A, Lecanda F, Marie PJ, et al. (2013) Zinc chelation: a metallothionein 2A’s mechanism of action involved in osteosarcoma cell death and chemotherapy resistance. Cit Cell Death Dis. [cited 2019 Jan 17];4. Available from: www.nature.com/cddis

  82. Si M, Lang J (2018) The roles of metallothioneins in carcinogenesis. J Hematol Oncol 11(1):1–21

    PubMed  PubMed Central  Google Scholar 

  83. Song X, Ji J, Gleason KJ, Yang F, Martignetti JA, Chen LS, Wang P (2019) Insights into impact of DNA copy number alteration and methylation on the proteogenomic landscape of human ovarian cancer via a multi-omics integrative analysis. [cited 2020 Feb 23]; Available from: https://doi.org/10.1074/mcp.RA118.001220

  84. Peterson SM, Freeman JL (2014) Chemical exposure generates DNA copy number variants and impacts gene expression. [cited 2020 Feb 23]; Available from: https://doi.org/10.1155/2014/984319

  85. Mishra S, Whetstine JR (2016) Different facets of copy number changes: permanent, transient, and adaptive. [cited 2020 Feb 23]; Available from: http://mcb.asm.org/

  86. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS (2007) Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 117(9):2713–2722

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M et al (2019) BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy. Int J Cancer 144(4):755–766 [cited 2020 Feb 23] Available from: http://doi.wiley.com/10.1002/ijc.31898

    CAS  PubMed  Google Scholar 

  88. Iyengar M, O’Hayer P, Cole A, Sebastian T, Yang K, Coffman L et al (2018) CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer. Oncotarget. 9(21):15658–15672

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Icon Cancer Centre, Southport, Australia

    Caitlin Phillips-Chavez

  2. Endeavour College of Natural Health, 105 Scarborough Street, Southport, QLD, 4215, Australia

    Caitlin Phillips-Chavez & Michael Watson

  3. Icon Cancer Centre, South Brisbane, Australia

    Jermaine Coward

  4. School of Medicine, University of Queensland, Brisbane, Australia

    Jermaine Coward

  5. Endeavour College of Natural Health, Level 2, 269 Wickham Street, Fortitude Valley, Brisbane, QLD, 4006, Australia

    Janet Schloss

Authors
  1. Caitlin Phillips-Chavez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jermaine Coward
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Janet Schloss
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Caitlin Phillips Chavez (CPC), Dr. Michael Watson (MW), A/Prof Jermaine Coward (JC) and Dr. Janet Schloss (JS) contributed to the concept of the literature review. MW and JS oversaw the implementation of the literature review. CPC and MW conducted database screening. MW and JS checked the citations from full text. CPC completed the literature analysis. CPC wrote the first draft of the manuscript. MW, JC and JS conducted critical review of the draft manuscript with significant contributions to draft revisions and approval of the final manuscript for publication. CPC completed the final draft of the manuscript.

Corresponding author

Correspondence to Caitlin Phillips-Chavez.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 58 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Phillips-Chavez, C., Watson, M., Coward, J. et al. A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients. Eur J Clin Pharmacol 76, 1059–1074 (2020). https://doi.org/10.1007/s00228-020-02874-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-020-02874-4

Keywords

Search

Navigation